Kura Oncology Inc. shares rose 11.6% in pre-market trading on Monday after the company's chairman and CEO, Troy Wilson, disclosed a purchase of 100,000 common shares through a revocable trust.
The purchase, made on August 24, 2026, was executed at a weighted average price of $12.39 per share, with individual trades ranging from $11.47 to $12.85. The total expenditure amounted to approximately $1.24 million. This transaction increased Wilson's beneficial ownership via the trust to 479,194 shares, in addition to 300,000 shares held through a separate philanthropic trust.
Wilson's latest purchase follows a similar open-market transaction on August 17, 2026, where he acquired another 100,000 shares for $1.11 million. The CEO's recent buying activity has contributed to the stock surpassing its 52-week high of $12.90.
Analysts have maintained a positive outlook on Kura Oncology. Citizens reiterated a Market Outperform rating with a price target of $24.00, citing strong commercial momentum for KOMZIFTI in treating relapsed/refractory NPM1-mutant acute myeloid leukemia. Jefferies also reaffirmed its buy rating.
The company's financial performance for the second quarter of 2026 showed an adjusted loss of $0.77 per share, beating the consensus estimate of $0.88. Revenue reached $20.87 million, exceeding expectations of $20.16 million.
Broader market indices reflected positive sentiment, with the S&P 500 up 0.5%, the Dow Jones up 0.6%, and the Nasdaq up 1.0%.
